Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lung SBRT followed by nivolumab + ipilimumab + platinum chemotherapy in first-line stage IV NSCLC
jRCTs031210688Phase 2Completed
- Sponsor
- North East Japan Study Group
- Start
- Mar 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, cisplatin, carboplatin, pemetrexed and 1 more in non-small cell lung cancer (NSCLC) (2 arms), sponsored by North East Japan Study Group. Primary endpoint: Progression-free survival rate at 6 months after enrollment. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031210688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210688.